Stand Up 2 Cancer

SU2C-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team

The SU2C-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team consists of a multidisciplinary group of experts that includes laboratory and clinical researchers, young investigators and senior scientists in the fields of immunotherapy, genetics, and pathology.

Co-leading the team are Penn Medicine's director of Translational Research, Robert Vonderheide, MD, DPhil, and Elizabeth M. Jaffee, MD, professor of oncology at the Johns Hopkins University School of Medicine and co-director of the Gastrointestinal Cancers Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Meet the Team

Why Pancreatic Cancer?

As the fourth leading cause of cancer death in the United States, pancreatic cancer remains one of the most deadly forms of cancer.

Survival rates are poor as more than 90 percent of pancreatic cancer patients die within the first year of diagnosis. Recent advancements have had little impact on patients'prognosis, and new pancreatic cancer treatments are desperately needed.

Learn more about pancreatic cancer

Why Immunotherapy?

Despite advances in treating cancer types with immunotherapy (hardwiring the body's immune system to fend off cancer as opposed to more traditional treatment options), clinical efforts focused specifically on pancreatic cancer lag behind, leaving new approaches to fight the disease in high demand.

Today, those diagnosed with the cancer, their caretakers and loved ones face a grim prognosis. To help alleviate this need in the pancreatic cancer community, Stand Up 2 Cancer is bringing together researchers, scientists, and doctors from institutions across the country to work together.